Regorafenib in the Real-Life Clinical Practice: Data from the
Czech Registry

J 2017

Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry

KOPEČKOVÁ, Kateřina, Tomáš BÜCHLER, Zbyněk BORTLÍČEK, Karel HEJDUK, Renata CHLOUPKOVÁ et. al.

Základní údaje

Originální název

Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry

Název česky

Regorafenib v reálné klinické praxi: Data z Českého registru

Autoři

KOPEČKOVÁ, Kateřina (203 Česká republika), Tomáš BÜCHLER (203 Česká republika), Zbyněk BORTLÍČEK (203 Česká republika, garant, domácí), Karel HEJDUK (203 Česká republika, domácí), Renata CHLOUPKOVÁ (203 Česká republika, domácí), Bohuslav MELICHAR (203 Česká republika), Petra POKORNÁ (203 Česká republika), Jiří TOMÁŠEK (203 Česká republika), Zdeněk LINKE (203 Česká republika), Luboš PETRUŽELKA (203 Česká republika), Igor KISS (203 Česká republika) a Jana PRAUSOVÁ (203 Česká republika)

Vydání

Targeted Oncology, Dordrecht, Springer, 2017, 1776-2596

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.907

Kód RIV

RIV/00216224:14110/17:00095942

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s11523-016-0458-1

UT WoS

000393121700009

Klíčová slova anglicky

Rheumatoid arthritis; Ultrasonography; Synovitis; Health assessment questionnaire

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 28. 1. 2021 11:25, Mgr. Tereza Miškechová

Anotace

V originále

Objective To describe the use of regorafenib for the treatment of metastatic colorectal cancer (mCRC) in clinical practice in the Czech Republic, and to describe the clinical outcomes of patients in terms of safety and survival. Patients and Methods The data of patients treated with regorafenib were extracted from the national CORECT registry. The CORECT registry is a non-interventional post-marketing database, gathering information about patients with CRC and treated with targeted agents. Twenty oncology centres in the Czech Republic contributed to this registry. Collected data included patients’ characteristics, disease history, cancer treatments, response to treatments and safety. Results A total of 148 patients treated with regorafenib in clinical practice were analysed. At regorafenib initiation, almost all patients were fully active or slightly restricted in physical activity. Regorafenib was not administered as first-line treatment in any patient. Median progression-free survival was 3.5 months and median overall survival was 9.3 months. One-year survival rate was 44.6 %. Four partial responses were observed and 51 stable diseases. Progression was observed in 66 patients (44.6 %). The main reported adverse events were skin toxicity (5.4 %) and fatigue (2.0 %). Conclusions Regorafenib is a well-established treatment for pretreated patients with mCRC, however real-life data are scarce. Our results demonstrated slightly better efficacy of regorafenib and better safety profile in patients with mCRC compared to the randomised trials.

Návaznosti

LM2015090, projekt VaV

Název: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Akronym: CZECRIN)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CZECRIN - Český národní uzel Evropské sítě infrastruktur klinického výzkumu

Citovat

KOPEČKOVÁ, Kateřina, Tomáš BÜCHLER, Zbyněk BORTLÍČEK, Karel HEJDUK, Renata CHLOUPKOVÁ, Bohuslav MELICHAR, Petra POKORNÁ, Jiří TOMÁŠEK, Zdeněk LINKE, Luboš PETRUŽELKA, Igor KISS a Jana PRAUSOVÁ. Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry. Targeted Oncology. Dordrecht: Springer, 2017, roč. 12, č. 1, s. 89-95. ISSN 1776-2596. Dostupné z: https://dx.doi.org/10.1007/s11523-016-0458-1.

@article{1362726,
   author = {Kopečková, Kateřina and Büchler, Tomáš and Bortlíček, Zbyněk and Hejduk, Karel and Chloupková, Renata and Melichar, Bohuslav and Pokorná, Petra and Tomášek, Jiří and Linke, Zdeněk and Petruželka, Luboš and Kiss, Igor and Prausová, Jana},
   article_location = {Dordrecht},
   article_number = {1},
   doi = {http://dx.doi.org/10.1007/s11523-016-0458-1},
   keywords = {Rheumatoid arthritis; Ultrasonography; Synovitis; Health assessment questionnaire},
   language = {eng},
   issn = {1776-2596},
   journal = {Targeted Oncology},
   title = {Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry},
   url = {http://dx.doi.org/10.1007/s11523-016-0458-1},
   volume = {12},
   year = {2017}
}

TY  - JOUR
ID  - 1362726
AU  - Kopečková, Kateřina - Büchler, Tomáš - Bortlíček, Zbyněk - Hejduk, Karel - Chloupková, Renata - Melichar, Bohuslav - Pokorná, Petra - Tomášek, Jiří - Linke, Zdeněk - Petruželka, Luboš - Kiss, Igor - Prausová, Jana
PY  - 2017
TI  - Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry
JF  - Targeted Oncology
VL  - 12
IS  - 1
SP  - 89-95
EP  - 89-95
PB  - Springer
SN  - 17762596
KW  - Rheumatoid arthritis
KW  - Ultrasonography
KW  - Synovitis
KW  - Health assessment questionnaire
UR  - http://dx.doi.org/10.1007/s11523-016-0458-1
L2  - http://dx.doi.org/10.1007/s11523-016-0458-1
N2  - Objective To describe the use of regorafenib for the treatment of metastatic colorectal cancer (mCRC) in clinical practice in the Czech Republic, and to describe the clinical outcomes of patients in terms of safety and survival. Patients and Methods The data of patients treated with regorafenib were extracted from the national CORECT registry. The CORECT registry is a non-interventional post-marketing database, gathering information about patients with CRC and treated with targeted agents. Twenty oncology centres in the Czech Republic contributed to this registry. Collected data included patients’ characteristics, disease history, cancer treatments, response to treatments and safety. Results A total of 148 patients treated with regorafenib in clinical practice were analysed. At regorafenib initiation, almost all patients were fully active or slightly restricted in physical activity. Regorafenib was not administered as first-line treatment in any patient. Median progression-free survival was 3.5 months and median overall survival was 9.3 months. One-year survival rate was 44.6 %. Four partial responses were observed and 51 stable diseases. Progression was observed in 66 patients (44.6 %). The main reported adverse events were skin toxicity (5.4 %) and fatigue (2.0 %). Conclusions Regorafenib is a well-established treatment for pretreated patients with mCRC, however real-life data are scarce. Our results demonstrated slightly better efficacy of regorafenib and better safety profile in patients with mCRC compared to the randomised trials.
ER  -

KOPEČKOVÁ, Kateřina, Tomáš BÜCHLER, Zbyněk BORTLÍČEK, Karel HEJDUK, Renata CHLOUPKOVÁ, Bohuslav MELICHAR, Petra POKORNÁ, Jiří TOMÁŠEK, Zdeněk LINKE, Luboš PETRUŽELKA, Igor KISS a Jana PRAUSOVÁ. Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry. \textit{Targeted Oncology}. Dordrecht: Springer, 2017, roč.~12, č.~1, s.~89-95. ISSN~1776-2596. Dostupné z: https://dx.doi.org/10.1007/s11523-016-0458-1.

Podrobný výpis o publikaci